Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

Por Mario Sznol, Adi Diab, Jonathan Zalevsky, Ute Hoch, Mehmet A Bilen, Giovanni Grignani, Nizar M Tannir, Erika Puente, Arjun V Balar, Daniel C Cho, Arlene O Siefker-Radtke, Lily Tang, David Chien, Arkopal Choudhury, Danni Yu, Sue L Currie, Mary A Tagliaferri, Michael E Hurwitz
Publicado em 2022-04-01